Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant subcutaneous interleukin-2 before sentinel lymph node biopsy or complete lymph node dissection in stage III melanoma
2011-001474-25Phase 2Terminated
- Sponsor
- Klinik für Dermatologie, Venerologie und Allergologie
- Start
- Sep 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in melanoma, sponsored by Klinik für Dermatologie, Venerologie und Allergologie. Primary endpoint: Complete pathological response rate. Started Sep 2011; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-001474-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001474-25.